Company Filing History:
Years Active: 2009-2012
Title: Innovations by Rebecca Aft
Introduction
Rebecca Aft is a notable inventor based in Chesterfield, MO (US). She has made significant contributions to the field of medicinal chemistry, particularly in the development of sigma receptor ligands. With a total of 2 patents, her work focuses on therapeutic applications that could potentially revolutionize cancer treatment.
Latest Patents
Rebecca Aft's latest patents include innovative compounds that target sigma receptors. One of her notable patents describes a series of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs. These compounds exhibit high affinity and selectivity for sigma 2 receptors compared to sigma 1 receptors. Among the disclosed compounds are biotinylated and fluorescent analogs, which can serve as probes for the sigma 2 receptor. Additionally, some of these compounds have shown the ability to induce apoptotic cell death through both caspase-dependent and caspase-independent mechanisms, making them effective for treating various solid tumors.
Career Highlights
Rebecca Aft is affiliated with Washington University, where she continues her research and development in the field of medicinal chemistry. Her work has the potential to lead to new chemotherapeutics or chemosensitizers that can improve treatment outcomes for cancer patients.
Collaborations
Rebecca has collaborated with esteemed colleagues such as Robert H Mach and Richard S Hotchkiss, contributing to the advancement of research in sigma receptor ligands.
Conclusion
Rebecca Aft's innovative work in developing sigma receptor ligands showcases her commitment to advancing cancer treatment. Her contributions are paving the way for new therapeutic options that could significantly impact patient care.